ScholarIQanswers from OpenAlex & ORCID
Hagop M. Kantarjian
ResearcherPublications, citations & collaboration network
Hagop M. Kantarjian is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Hagop M. Kantarjian have?
ScholarIQindexed works
Hagop M. Kantarjian has 5,585 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Hagop M. Kantarjian have?
ScholarIQcitation count
Hagop M. Kantarjian has 271,069 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Hagop M. Kantarjian?
ScholarIQh-index
Hagop M. Kantarjian has an h-index of 233 in OpenAlex.
What is the i10-index of Hagop M. Kantarjian?
ScholarIQi10-index
Hagop M. Kantarjian has an i10-index of 2,526 in OpenAlex.
What is the ORCID of Hagop M. Kantarjian?
ScholarIQorcid
The ORCID for Hagop M. Kantarjian is on the source record.
What is the OpenAlex record for Hagop M. Kantarjian?
ScholarIQopenalex
The OpenAlex for Hagop M. Kantarjian is on the source record.
What are the most-cited papers on Hagop M. Kantarjian?
ScholarIQmost cited works
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
Andreas Hochhaus, Michele Baccarani, Richard T. Silver, CA Schiffer, Jane F. Apperley, Francisco Cervantes, R E Clark, J. E. Cortes, Michael W. Deininger, François Guilhot, Henrik Hjorth‐Hansen, Timothy P. Hughes, J. Janssen, Hagop M. Kantarjian, D. W. Kim, Richard A. Larson, J. H. Lipton, F.-X. Mahon, Jiří Mayer, Franck E. Nicolini, D Niederwieser, Fabrizio Pane, Jerald P. Radich, Delphine Réa, Johan Richter, G Rosti, Philipe Rousselot, Giuseppe Saglio, Susanne Saußele, Simona Soverini, J. L. Steegmann, Anna Turkina, Andrey Zaritskey, R. Hehlmann
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia
Constantine S. Tam, Susan O’Brien, William G. Wierda, Hagop M. Kantarjian, Sijin Wen, Kim‐Anh Do, Deborah A. Thomas, Jörge E. Cortes, Susan Lerner, Michael J. Keating
Chemoimmunotherapy With Fludarabine, Cyclophosphamide, and Rituximab for Relapsed and Refractory Chronic Lymphocytic Leukemia
William G. Wierda, Susan O’Brien, Sijin Wen, Stefan Faderl, Guillermo Garcia‐Manero, Deborah A. Thomas, Kim‐Anh Do, Jörge E. Cortes, Charles Koller, Miloslav Beran, Alessandra Ferrajoli, Francis J. Giles, Susan Lerner, Maher Albitar, Hagop M. Kantarjian, Michael J. Keating
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I
Srđan Verstovšek, Ruben A. Mesa, Jason Gotlib, R. S. Levy, Vikas Gupta, John F. DiPersio, John Catalano, Michael W. Deininger, Carole B. Miller, Richard T. Silver, Moshe Talpaz, E. Winton, Jimmie H. Harvey, Murat O. Arcasoy, Elizabeth O. Hexner, Roger M. Lyons, Azra Raza, Kris Vaddi, William Sun, Wei Peng, V. Sandor, Hagop M. Kantarjian, For the COMFORT-I investigators
Clinical Outcomes and Prognostic Factors in Patients With Richter's Syndrome Treated With Chemotherapy or Chemoimmunotherapy With or Without Stem-Cell Transplantation
Apostolia M. Tsimberidou, Susan O’Brien, Issa F. Khouri, Francis J. Giles, Hagop M. Kantarjian, Richard E. Champlin, Sijin Wen, Kim‐Anh Do, Susan Smith, Susan Lerner, Emil J. Freireich, Michael J. Keating